A Study of Revumenib and Mezigdomide in People With Leukemia
Status:
RECRUITING
Trial end date:
2029-01-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.